Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE): Rationale and design - 11/10/23
, Hasan K. Siddiqi, MD, MSCR c, Lynne W. Stevenson, MD c, Brian Bales, MD d, Jin H. Han, MD, MScd d, e, Kimberly Hart, MA f, Brant Imhoff, MSc f, Juan B. Ivey-Miranda, MD g, h, Cathy A. Jenkins, MS f, JoAnn Lindenfeld, MD c, Matthew S. Shotwell, PhD f, Karen F. Miller, RN, MPA d, Henry Ooi, MD c, i, Veena S. Rao, PhD g, Kelly Schlendorf, MD c, Wesley H. Self, MD, MPH d, Edward D. Siew, MD c, Alan Storrow, MD d, Ryan Walsh, MD d, Jesse O. Wrenn, MD d, Jeffrey M. Testani, MD, MTR g, Sean P. Collins, MD, MSc d, eAbstract |
Diuresis to achieve decongestion is a central aim of therapy in patients hospitalized for acute decompensated heart failure (ADHF). While multiple clinical trials have investigated initial diuretic strategies for a designated period of time, there is a paucity of evidence to guide diuretic titration strategies continued until decongestion is achieved. The use of urine chemistries (urine sodium and creatinine) in a natriuretic response prediction equation accurately estimates natriuresis in response to diuretic dosing, but a randomized clinical trial is needed to compare a urine chemistry-guided diuresis strategy with a strategy of usual care. The urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE) trial is designed to test the hypothesis that protocolized diuretic therapy guided by spot urine chemistry through completion of intravenous diuresis will be superior to usual care and improve outcomes over the 14 days following randomization. ESCALATE will randomize and obtain complete data on 450 patients with acute heart failure to a diuretic strategy guided by urine chemistry or a usual care strategy. Key inclusion criteria include an objective measure of hypervolemia with at least 10 pounds of estimated excess volume, and key exclusion criteria include significant valvular stenosis, hypotension, and a chronic need for dialysis. Our primary outcome is days of benefit over the 14 days after randomization. Days of benefit combines patient symptoms captured by global clinical status with clinical state quantifying the need for hospitalization and intravenous diuresis.
Clinical trial registration |
NCT04481919.
Le texte complet de cet article est disponible en PDF.Plan
Vol 265
P. 121-131 - novembre 2023 Retour au numéro
Article précédent
- Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study
- Niels M.R. van der Sangen, I. Tarik Küçük, Shabiga Sivanesan, Yolande Appelman, Jurriën M. ten Berg, Ashley Verburg, Jaouad Azzahhafi, E. Karin Arkenbout, Wouter J. Kikkert, Ron Pisters, J. Wouter Jukema, Fatih Arslan, Arnoud van ‘t Hof, Mustafa Ilhan, Loes P. Hoebers, René J. van der Schaaf, Peter Damman, Pier Woudstra, Tim P. van de Hoef, Matthijs Bax, Rutger L. Anthonio, Jawed Polad, Tom Adriaenssens, Willem Dewilde, Carlo Zivelonghi, Peep Laanmets, Risko Majas, Marcel G.W. Dijkgraaf, Bimmer E.P.M. Claessen, José P.S. Henriques
- Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI
- Raffaele Piccolo, Paolo Calabrò, Attilio Varricchio, Cesare Baldi, Giovanni Napolitano, Ciro De Simone, Ciro Mauro, Eugenio Stabile, Gianluca Caiazzo, Tullio Tesorio, Marco Boccalatte, Bernardino Tuccillo, Giuseppe Bottiglieri, Enrico Russolillo, Emilio Di Lorenzo, Greta Carrara, Salvatore Cassese, Sergio Leonardi, Simone Biscaglia, Francesco Costa, Eugene McFadden, Dik Heg, Anna Franzone, Giulio G. Stefanini, Davide Capodanno, Giovanni Esposito
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?